Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials.

Hawkey CJ, Laine L, Harper SE, Quan HU, Bolognese JA, Mortensen E; Rofecoxib Osteoarthritis Endoscopy Multinational Study Group.

Aliment Pharmacol Ther. 2001 Oct;15(10):1593-601.

2.

Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.

Hawkey CJ, Jackson L, Harper SE, Simon TJ, Mortensen E, Lines CR.

Aliment Pharmacol Ther. 2001 Jan;15(1):1-9. Review.

3.
4.

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group.

N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528.

5.
6.

A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects.

Hunt RH, Bowen B, Mortensen ER, Simon TJ, James C, Cagliola A, Quan H, Bolognese JA.

Am J Med. 2000 Aug 15;109(3):201-6.

PMID:
10974182
7.

A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group.

Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, Helgetveit KB, Kress B, Daniels B, Bolognese J, Krupa D, Seidenberg B, Ehrich E.

Arch Intern Med. 2000 Jun 26;160(12):1781-7.

PMID:
10871971
10.

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.

Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ.

JAMA. 1999 Nov 24;282(20):1929-33.

PMID:
10580458
11.

Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial.

Morrison BW, Daniels SE, Kotey P, Cantu N, Seidenberg B.

Obstet Gynecol. 1999 Oct;94(4):504-8.

PMID:
10511349
12.
13.

Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen.

Lanza FL, Rack MF, Simon TJ, Quan H, Bolognese JA, Hoover ME, Wilson FR, Harper SE.

Aliment Pharmacol Ther. 1999 Jun;13(6):761-7.

14.

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

Wolfe MM, Lichtenstein DR, Singh G.

N Engl J Med. 1999 Jun 17;340(24):1888-99. Review. No abstract available. Erratum in: N Engl J Med 1999 Aug 12;341(7):548.

PMID:
10369853
15.

Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.

Ehrich EW, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, Porras A, Wittreich J, Seibold JR, De Schepper P, Mehlisch DR, Gertz BJ.

Clin Pharmacol Ther. 1999 Mar;65(3):336-47.

PMID:
10096266
16.

High-dose famotidine for prevention of NSAID ulcers?

Graham DY.

Gastroenterology. 1997 Jun;112(6):2143-5. No abstract available.

PMID:
9178711
17.

Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group.

Graham DY, White RH, Moreland LW, Schubert TT, Katz R, Jaszewski R, Tindall E, Triadafilopoulos G, Stromatt SC, Teoh LS.

Ann Intern Med. 1993 Aug 15;119(4):257-62.

PMID:
8328732
18.

Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.

Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K.

Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3228-32.

19.

Towards a better aspirin.

Vane J.

Nature. 1994 Jan 20;367(6460):215-6. No abstract available.

PMID:
8121485
20.

Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain.

Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, Lee L, Isakson P.

Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12013-7.

Supplemental Content

Support Center